Mendus AB (publ) (IMMU) - Total Liabilities

Latest as of December 2025: Skr43.26 Million SEK ≈ $4.66 Million USD

Based on the latest financial reports, Mendus AB (publ) (IMMU) has total liabilities worth Skr43.26 Million SEK (≈ $4.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Mendus AB (publ) cash flow conversion to assess how effectively this company generates cash.

Mendus AB (publ) - Total Liabilities Trend (2009–2025)

This chart illustrates how Mendus AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Mendus AB (publ) to evaluate the company's liquid asset resilience ratio.

Mendus AB (publ) Competitors by Total Liabilities

The table below lists competitors of Mendus AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
POLARIS WORKS Inc
KQ:123010
Korea ₩21.88 Billion
Acarix A/S
ST:ACARIX
Sweden Skr10.16 Million
Gabriel Resources Ltd
V:GBU
Canada CA$23.73 Million
Sterling Metals Corp
V:SAG
Canada CA$310.10K
Subur Tiasa Holdings Bhd
KLSE:6904
Malaysia RM748.15 Million
Puloon Technology Inc
KQ:094940
Korea ₩7.37 Billion
Atende S.A.
WAR:ATD
Poland zł171.45 Million

Liability Composition Analysis (2009–2025)

This chart breaks down Mendus AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Mendus AB (publ).

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.70 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 2.38 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mendus AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mendus AB (publ) (2009–2025)

The table below shows the annual total liabilities of Mendus AB (publ) from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 Skr43.26 Million
≈ $4.66 Million
-15.54%
2024-12-31 Skr51.22 Million
≈ $5.51 Million
-0.02%
2023-12-31 Skr51.23 Million
≈ $5.51 Million
-51.65%
2022-12-31 Skr105.95 Million
≈ $11.40 Million
+64.92%
2021-12-31 Skr64.24 Million
≈ $6.91 Million
-4.92%
2020-12-31 Skr67.57 Million
≈ $7.27 Million
+117.62%
2019-12-31 Skr31.05 Million
≈ $3.34 Million
-29.96%
2018-12-31 Skr44.33 Million
≈ $4.77 Million
-21.66%
2017-12-31 Skr56.59 Million
≈ $6.09 Million
+194.98%
2016-12-31 Skr19.18 Million
≈ $2.06 Million
+27.39%
2015-12-31 Skr15.06 Million
≈ $1.62 Million
+135.04%
2014-12-31 Skr6.41 Million
≈ $689.52K
-31.06%
2013-12-31 Skr9.29 Million
≈ $1.00 Million
+344.35%
2012-12-31 Skr2.09 Million
≈ $225.08K
+26.97%
2011-12-31 Skr1.65 Million
≈ $177.28K
-29.20%
2010-12-31 Skr2.33 Million
≈ $250.40K
+113.00%
2009-12-31 Skr1.09 Million
≈ $117.56K
--

About Mendus AB (publ)

ST:IMMU Sweden Biotechnology
Market Cap
$33.83 Million
Skr314.38 Million SEK
Market Cap Rank
#23308 Global
#446 in Sweden
Share Price
Skr5.13
Change (1 day)
+4.91%
52-Week Range
Skr3.96 - Skr10.02
All Time High
Skr737.49
About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more